ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBRX ImmunityBio, Inc.

未开盘 04-07 16:00:00 EDT

6.86

-0.22

-3.11%

盘后7.14

+0.28+4.08%

19:59 EDT

最高7.00	最低6.68	成交量1,298万
今开6.98	昨收7.08	日振幅4.52%
总市值70.52亿	流通市值23.05亿	总股本10.28亿
成交额8,838万	换手率3.86%	流通股本3.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBRX","market":"US","secType":"STK","nameCN":"ImmunityBio, Inc.","latestPrice":6.86,"timestamp":1775592000000,"preClose":7.08,"halted":0,"volume":12979132,"hourTrading":{"tag":"盘后","latestPrice":7.14,"preClose":6.86,"latestTime":"19:59 EDT","volume":888569,"amount":6271902.0645,"timestamp":1775606399355,"change":0.28,"changeRate":0.040816,"amplitude":0.050087},"delay":0,"changeRate":-0.03107344632768358,"floatShares":336000000,"shares":1027999999,"eps":-0.382011,"marketStatus":"未开盘","change":-0.22,"latestTime":"04-07 16:00:00 EDT","open":6.98,"high":7,"low":6.68,"amount":88375553.5529472,"amplitude":0.045198,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.382011,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1775635200000},"marketStatusCode":0,"adr":0,"listingDate":1438056000000,"exchange":"NASDAQ","adjPreClose":7.08,"preHourTrading":{"tag":"盘前","latestPrice":6.97,"preClose":7.08,"latestTime":"09:27 EDT","volume":329319,"amount":2301588.6242184,"timestamp":1775568460595,"change":-0.11,"changeRate":-0.015537,"amplitude":0.031243},"postHourTrading":{"tag":"盘后","latestPrice":7.14,"preClose":6.86,"latestTime":"19:59 EDT","volume":888569,"amount":6271902.0645,"timestamp":1775606399355,"change":0.28,"changeRate":0.040816,"amplitude":0.050087},"volumeRatio":0.678854,"impliedVol":1.3158,"impliedVolPercentile":0.7912},"requestUrl":"/m/hq/s/IBRX","defaultTab":"news","newsList":[{"id":"1112712244","title":"ImmunityBio, Inc. 采取纠正措施，包括高管培训及引入外部监管法律顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=1112712244","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112712244?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:32","pubTimestamp":1775475131,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc. 已开始实施一系列纠正措施，以加强公司治理与合规体系。这些举措包括为高级管理人员提供专项培训，并聘请外部监管法律顾问提供专业指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111954531","title":"ImmunityBio 通过1亿美元融资交易强化资产负债表，其中7500万美元为非稀释性融资，支持全球扩张及免疫疗法管线拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=1111954531","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111954531?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:32","pubTimestamp":1774956774,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc. 宣布完成总额达1亿美元的融资交易，显著增强公司财务结构。此次融资包含7500万美元的非稀释性资金，旨在为其全球市场扩张计划及更广泛的免疫疗法研发管线提供资金支持。该举措将助力公司推进创新疗法的开发，进一步巩固其在免疫治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132066095","title":"ImmunityBio公司：IDMC确认366名患者研究具备足够统计效力检测完全缓解率差异","url":"https://stock-news.laohu8.com/highlight/detail?id=1132066095","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132066095?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:40","pubTimestamp":1774525222,"startTime":"0","endTime":"0","summary":"独立数据监察委员会（IDMC）已确认，ImmunityBio公司针对366名患者开展的临床研究具备充分的统计效力，能够有效检测治疗组间完全缓解率的差异性差异。\n该研究设计确保了在评估主要终点时具有足够的统计学把握度，为临床试验结果的可靠性提供了重要保障。完全缓解率作为关键疗效指标，其差异的检测能力对后续研究结论具有决定性意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166959029","title":"ImmunityBio确认关键随机BCG初治NMIBC试验具备统计学效力，可检测Anktiva®联合BCG与单用BCG的临床意义差异；补充BLA提交计划于2026年完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1166959029","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166959029?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:31","pubTimestamp":1774524679,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.宣布，其关键性随机BCG初治非肌层浸润性膀胱癌（NMIBC）试验已证实具备足够的统计学效力，能够检测出Anktiva®联合BCG治疗方案与单用BCG方案之间存在的临床意义差异。\n该公司同时确认，针对该疗法的补充生物制剂许可申请（BLA）提交工作正按计划推进，目标在2026年完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111334106","title":"ImmunityBio确认收到FDA关于Anktiva®推广材料的相关函件","url":"https://stock-news.laohu8.com/highlight/detail?id=1111334106","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111334106?lang=zh_cn&edition=full","pubTime":"2026-03-24 23:25","pubTimestamp":1774365915,"startTime":"0","endTime":"0","summary":"生物技术公司ImmunityBio, Inc.近日宣布，已正式收到美国食品药品监督管理局（FDA）药品营销、广告和传播办公室（OPDP）于3月13日发出的信函。该函件主要针对其肿瘤免疫治疗药物Anktiva®（通用名：Nogapendekin Alfa Inbakicept-PMLN）的部分推广宣传材料提出了相关意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7e2294d99a26f40e351ca07cad557479","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115161464","title":"ImmunityBio高度重视FDA关切，已启动法律与监管团队联合审查信函","url":"https://stock-news.laohu8.com/highlight/detail?id=1115161464","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115161464?lang=zh_cn&edition=full","pubTime":"2026-03-24 23:25","pubTimestamp":1774365914,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc. 近日宣布，公司已正式启动针对美国食品药品监督管理局（FDA）所发信函的全面审查程序。此次审查将由公司内部法律顾问与监管事务团队协同推进，旨在深入评估FDA提出的各项关切事项。\n该公司强调，其管理层高度重视监管机构的反馈意见，并将以审慎态度处理相关事宜。目前，审查工作正在有序开展，后续进展将适时向市场披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102506551","title":"美国FDA向ImmunityBio公司发出警告信 指其Anktiva电视广告及播客内容存在虚假误导","url":"https://stock-news.laohu8.com/highlight/detail?id=1102506551","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102506551?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:27","pubTimestamp":1774362440,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已对生物技术公司ImmunityBio, Inc.采取监管行动，就其抗癌药物Anktiva的相关宣传材料发出正式警告信。监管机构指出，该公司通过电视广告和播客渠道发布的推广内容存在\"虚假或误导性\"表述，违反了药品营销规范。根据监管程序，ImmunityBio公司需在收到警告信15个工作日内提交整改方案，明确具体纠正措施。若未能及时回应或整改不到位，FDA可能采取更严厉的处罚手段，包括但不限于罚款、强制撤回广告乃至暂停相关产品的市场推广许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7e2294d99a26f40e351ca07cad557479","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139354509","title":"异动解读 | ImmunityBio宣布财年业绩发布会，股价盘后大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139354509","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139354509?lang=zh_cn&edition=full","pubTime":"2026-02-28 07:41","pubTimestamp":1772235669,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（纳斯达克代码：IBRX）今日盘后股价大涨5.11%，引起了市场的广泛关注。消息面上，公司宣布将于近期举行2025财年财务业绩发布会，届时管理层将详细介绍业务最新进展，并对全年财务数据进行全面解读。此次会议为投资者提供了深入了解公司战略布局与未来发展动向的重要窗口，市场对此反应积极。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145904961","title":"ImmunityBio将于2026年3月3日公布2025财年业绩并召开业务进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1145904961","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145904961?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:31","pubTimestamp":1772195485,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（纳斯达克代码：IBRX）宣布，将于2026年3月3日（星期二）举行2025财年财务业绩发布会。届时，公司管理层将详细介绍业务最新进展，并对全年财务数据进行全面解读。此次会议将为投资者提供深入了解公司战略布局与未来发展动向的重要窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161242854","title":"异动解读 | ImmunityBio完成关键试验患者招募，盘前大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161242854","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161242854?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:03","pubTimestamp":1772111033,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（股票代码：IBRX）今日盘前股价大幅上涨5.14%，引起了市场的关注。消息面上，公司宣布已顺利完成一项关键性随机试验的患者招募工作，该试验旨在评估其核心产品Anktiva®联合卡介苗（BCG）对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。这一进展被视为公司在膀胱癌创新疗法开发领域的重要里程碑，增强了投资者对其研发管线未来潜力的信心，从而推动了股价上涨。这项研究的完成为后续的数据分析和结果公布奠定了坚实基础，市场期待该疗法能为患者带来新的治疗选择，并可能为公司创造新的增长动力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110407487","title":"ImmunityBio完成关键随机试验患者招募：评估Anktiva®联合BCG对比单用BCG治疗BCG初治非肌层浸润性膀胱癌原位癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1110407487","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110407487?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:36","pubTimestamp":1772109384,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc. (简称ImmunityBio) 已顺利完成一项关键性随机试验的患者招募工作。该试验旨在评估其核心产品Anktiva®联合卡介苗(BCG)的治疗方案，对比单用BCG，在治疗BCG初治型非肌层浸润性膀胱癌原位癌患者中的疗效与安全性。\n这项研究的完成标志着公司在膀胱癌创新疗法开发领域迈出了重要一步，为后续的数据分析和结果公布奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194003678","title":"ImmunityBio, Inc. 年营收同比飙升700%，Anktiva®获肺癌适应症扩展批准，并与33国达成全球商业合作及标签扩展计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1194003678","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194003678?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:01","pubTimestamp":1771848075,"startTime":"0","endTime":"0","summary":"生物技术公司ImmunityBio, Inc. 宣布其年营收实现同比700%的惊人增长。公司核心产品Anktiva®在肺癌领域的适应症获得进一步批准，标志着其治疗版图的重大扩展。此外，公司已成功与全球33个国家建立商业合作伙伴关系，并制定了全球范围内的标签扩展计划，旨在将创新疗法带给更广泛的患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164733354","title":"ImmunityBio携手Biopharma与Cigalah Healthcare在沙特阿拉伯推出Anktiva®，惠及膀胱癌与肺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1164733354","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164733354?lang=zh_cn&edition=full","pubTime":"2026-02-20 21:35","pubTimestamp":1771594549,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.已与Biopharma及Cigalah Healthcare达成合作，将在沙特阿拉伯市场正式推出其创新疗法Anktiva®。该药物旨在为当地的膀胱癌和肺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132611587","title":"ImmunityBio携手新分销伙伴拓展Anktiva®欧盟市场 并成立爱尔兰子公司支持欧洲上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1132611587","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132611587?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:04","pubTimestamp":1771509852,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.宣布通过新的分销合作扩大其创新药物Anktiva®在欧盟地区的可及性，同时正式成立爱尔兰子公司，为产品在欧洲市场的全面推广提供战略支持。这一系列举措标志着该公司在欧洲商业化布局的重要里程碑。\n新建立的合作伙伴关系将有效提升Anktiva®在欧盟各国的分销效率，确保患者能够及时获得这一前沿疗法。爱尔兰子公司的设立将进一步强化本地化运营能力，为欧洲市场提供更精准的临床支持和商业化服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157842511","title":"ImmunityBio获欧盟委员会批准Anktiva®联合BCG治疗非肌层浸润性膀胱癌原位癌，全球准入范围扩至33国","url":"https://stock-news.laohu8.com/highlight/detail?id=1157842511","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157842511?lang=zh_cn&edition=full","pubTime":"2026-02-18 22:01","pubTimestamp":1771423277,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（纳斯达克代码：IBRX）宣布，其创新疗法Anktiva®（nogapendekin alfa inbakicept）联合卡介苗（BCG）已获得欧盟委员会批准，用于治疗非肌层浸润性膀胱癌（NMIBC）的原位癌（CIS）患者。此项授权标志着该疗法在欧洲经济区（EEA）的30个成员国以及冰岛、列支敦士登和挪威共33个国家获得上市许可，将显著提升全球患者对该前沿治疗方案的获取机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612414397","title":"Immunitybio, Inc.盘中异动 早盘股价大涨5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612414397","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612414397?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:30","pubTimestamp":1771338627,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日22时30分，Immunitybio, Inc.股票出现波动，股价急速上涨5.47%。Immunitybio, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Immunitybio, Inc.公司简介：ImmunityBio Inc是一家综合性临床阶段生物技术公司，致力于发现、开发和商业化下一代免疫和细胞疗法，以增强自然免疫系统，从而驱动和维持免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223027a4ad8529&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223027a4ad8529&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120348816","title":"ImmunityBio启动ANKTIVA®联合CAR-NK细胞疗法2期临床试验，探索无化疗方案治疗惰性淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1120348816","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120348816?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:08","pubTimestamp":1770034122,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（纳斯达克代码：IBRX）近日宣布启动一项2期临床研究，评估其核心产品ANKTIVA®（通用名resq215b）与嵌合抗原受体自然杀伤细胞（CAR-NK）疗法联合用于惰性淋巴瘤治疗的潜力。该试验的创新之处在于采用完全无化疗的治疗策略，旨在通过生物免疫疗法精准靶向肿瘤细胞，减少传统化疗带来的毒副作用。若研究结果积极，有望为惰性淋巴瘤患者提供更安全、耐受性更高的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198499689","title":"ImmunityBio, Inc.临床试验：三名受试者出现疑似与实验疗法相关的严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1198499689","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198499689?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:03","pubTimestamp":1769169797,"startTime":"0","endTime":"0","summary":"在ImmunityBio, Inc.进行的一项临床研究中，有三名参与试验的受试者报告出现了严重不良事件。目前，这些事件被怀疑与该公司所研发的实验性疗法存在关联。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154477526","title":"ImmunityBio公布：接受Anktiva®联合CAR-NK无化疗疗法的复发性胶质母细胞瘤患者中位总生存期尚未达到，淋巴细胞减少症得以逆转","url":"https://stock-news.laohu8.com/highlight/detail?id=1154477526","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154477526?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:01","pubTimestamp":1769169688,"startTime":"0","endTime":"0","summary":"ImmunityBio公司最新报告显示，在采用Anktiva®联合CAR-NK细胞疗法的复发性胶质母细胞瘤患者中，中位总生存期数据尚未达到可统计的终点。这一无化疗治疗方案不仅展现出延长生存期的潜力，更值得注意的是，患者先前存在的淋巴细胞减少症出现了显著逆转。\n该疗法通过激活患者自身的免疫系统对抗肿瘤，为传统治疗手段效果有限的脑癌患者提供了新的希望。淋巴细胞计数的恢复表明免疫功能得到改善，这可能为提升抗肿瘤疗效奠定基础。\n研究结果凸显了Anktiva®与CAR-NK联合疗法的双重优势：既可能延长生存期，又能逆转化疗常见副作用带来的免疫抑制状态。这一突破性进展为晚期脑癌治疗开辟了全新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124337225","title":"异动解读 | ImmunityBio盘中大跌10.11%，因FDA要求提供膀胱癌药物更广泛应用信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1124337225","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124337225?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:33","pubTimestamp":1769005984,"startTime":"0","endTime":"0","summary":"ImmunityBio, Inc.（IBRX）今日盘中股价大跌10.11%，引发了市场的广泛关注。消息面上，美国食品和药物管理局（FDA）要求该公司提供更多信息，以支持其膀胱癌药物Anktiva在更广泛患者群体中的使用申请。这一请求可能引发了投资者对审批进程延迟或额外要求的担忧，从而导致股价大幅下跌。ImmunityBio表示，FDA并未要求进行新的临床试验，但需要补充某些信息以支持重新提交的申请。公司计划在未来30天内提交所需信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IBRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunitybio.com","stockEarnings":[{"period":"1week","weight":-0.1056},{"period":"1month","weight":-0.2088},{"period":"3month","weight":2.1182},{"period":"6month","weight":1.8115},{"period":"1year","weight":1.5221},{"period":"ytd","weight":2.4646}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ImmunityBio, Inc.于2002年10月7日在伊利诺伊州ZelleRx Corporation公司的名义下注册成立，于2010年1月22日，公司更名为Conkwest股份有限公司。ImmunityBio是一家领先的晚期免疫治疗公司，可激活先天和适应性免疫系统，以治疗肿瘤学和传染病领域内严重未满足的需求。公司是一家领先的临床剂型的现成自然杀伤细胞疗法生产商，记忆NK细胞，连同抗体细胞因子融合蛋白、白蛋白结合化学免疫调节剂和疫苗载体的综合平台。通过结合这些NK、巨噬细胞和T细胞激活平台，该公司相信ImmunityBio在免疫治疗领域处于领先地位，具有跨越多种肿瘤类型和传染病的后期临床开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.219152},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075725},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.095867},{"month":4,"riseRate":0.454545,"avgChangeRate":0.010074},{"month":5,"riseRate":0.4,"avgChangeRate":0.054052},{"month":6,"riseRate":0.3,"avgChangeRate":0.132356},{"month":7,"riseRate":0.4,"avgChangeRate":-0.029239},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.110134},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.03348},{"month":10,"riseRate":0.454545,"avgChangeRate":0.029893},{"month":11,"riseRate":0.636364,"avgChangeRate":0.121867},{"month":12,"riseRate":0.363636,"avgChangeRate":0.048951}],"exchange":"NASDAQ","name":"ImmunityBio, Inc.","nameEN":"ImmunityBio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ImmunityBio, Inc.,IBRX,ImmunityBio, Inc.股票,ImmunityBio, Inc.股票老虎,ImmunityBio, Inc.股票老虎国际,ImmunityBio, Inc.行情,ImmunityBio, Inc.股票行情,ImmunityBio, Inc.股价,ImmunityBio, Inc.股市,ImmunityBio, Inc.股票价格,ImmunityBio, Inc.股票交易,ImmunityBio, Inc.股票购买,ImmunityBio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ImmunityBio, Inc.(IBRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ImmunityBio, Inc.(IBRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}